Abbott (NYSE:ABT) announced today that the Galien Foundation picked its FreeStyle Libre continuous glucose monitor (CGM) for a major award. The foundation named FreeStyle Libre as the best “Best Medical Technology” of the last 50 years. Other medtech receiving the designation included Edwards Lifesciences’ Sapien 3 Ultra TAVR and Roche’s Cobas HPV test. This announcement […]
Technology
Kennesaw State researchers aim to improve glucose monitoring with non-invasive tech
Kennesaw State University researchers developed a way to improve the glucose monitoring process for those living with diabetes. Maria Valero, an assistant professor of information technology at KSU’s College of Computing and Software Engineering (CCSE) and director of its IoT as a Service Research Group undertook the mission after watching her diabetic father use fingersticks […]
Better Therapeutics names new chief commercial officer
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Diane Gomez-Thinnes as its new chief commercial officer (CCO). Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, […]
How Dexcom uses wearables to deliver differentiated diabetes management
Dexcom (Nasdaq:DXCM) is one of the leaders in the diabetes technology space with its continuous glucose monitoring (CGM) technology. The company’s current-generation Dexcom G6 CGM remains one of the biggest players in the CGM space. Meanwhile, its next-generation Dexcom G7 CGM has already launched in a number of countries overseas. The wearable device — which […]
Dexcom launches NIL program for college athletes with diabetes
Dexcom (Nasdaq:DXCM) announced today that it launched Dexcom U, an NIL (name, image, likeness) program for college athletes. The San Diego-based company aims for the program to celebrate college athletes with diabetes. The company labeled it the first-ever NIL program designed to do so. Dexcom also hopes it inspires those with diabetes to pursue athletic […]
Medtronic launches diabetes insights program for MiniMed users
Medtronic (NYSE:MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump. The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system. Using an individual’s data, My Insight provides personalized tips, trends and […]
GlucoTrack to begin R&D for new long-term CGM
GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM). Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market. Initial data gives the company confidence […]
Ascensia completes Senseonics Eversense E3 European launch
Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3. Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM. Ascensia said in a news release […]
Analysts: Abbott, Dexcom to benefit from proposed CMS decision on CGMs
Analysts see a new proposed local coverage determination (LCD) from CMS as a potential boost for Dexcom (Nasdaq:DXCM) and Abbott (NYSE:ABT). The Centers for Medicare and Medicaid Services (CMS) yesterday published the LCD modifying coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history […]
Published data backs digital therapeutic for diabetes from Better Therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that newly published data supports its digital therapeutic for type 2 diabetes. San Francisco-based Better Therapeutics develops the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. In July, the company completed the pivotal trial for its BT-001 digital therapeutic […]